Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial

Abhishek, Abhishek; Peckham, Nicholas; Pade, Corinna; Gibbons, Joseph M.; Cureton, Lucy; Francis, Anne; Barber, Vicki; Williams, Jennifer A. E.; Appelbe, Duncan; Eldridge, Lucy; Julier, Patrick; Altmann, Daniel M.; Bluett, James; Brooks, Tim; Coates, Laura C.; Rombach, Ines; Semper, Amanda; Otter, Ashley; Valdes, Ana M.; Nguyen-Van-Tam, Jonathan S.; Williams, Hywel C.; Boyton, Rosemary J.; McKnight, Áine; Cook, Jonathan A.; Study investigators, VROOM

doi:10.1016/S2665-9913(23)00298-9

All Outputs (2)

Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study (2024)
Journal Article

Objective The uptake and safety of pneumococcal vaccination in people with immune mediated inflammatory diseases (IMIDs) is poorly understood. We investigated the UK wide pneumococcal vaccine uptake in adults with IMIDs and explored the association b... Read More about Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study.

Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial (2023)
Journal Article

Background Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improv... Read More about Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial.